Scinai Immunotherapeutics SCNI
NASDAQ SCNI
$0.70 -0.05 (-6.62%)
As of: Oct 20, 2026 · 10:25 AM EDT

Scinai Immunotherapeutics (SCNI) Operating Margin (2024 - 2026)

Updated

Scinai Immunotherapeutics (SCNI) recorded Operating Margin of -466.52% in Q2 2026, up 707.28 percentage points from -1173.80% a year earlier and up 37.98 percentage points from the prior quarter.

Analysis

Scinai Immunotherapeutics (SCNI) Operating Margin (2024 - 2026) Analysis & Trends

On a TTM basis, Scinai Immunotherapeutics' Operating Margin came in at -486.41% as of Jun 30, 2026, up 249.94 percentage points year-over-year; for FY2025, it was -407.91%, up 904.85 percentage points from FY2024.

  • Across earlier years, Operating Margin came in at -1312.77% in FY2024.
  • The Q2 2026 figure is the highest quarterly Operating Margin since Q1 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Operating Margin (Qtr)
1 Eli Lilly 1,163.56 Bn 1,132.15 Bn 19.71 Bn 51.16%
2 Johnson & Johnson 624.15 Bn 542.68 Bn 17.26 Bn 28.21%
3 AbbVie 509.05 Bn 482.17 Bn 12.70 Bn 37.86%
4 Merck 365.71 Bn 320.09 Bn 12.21 Bn -3.52%
5 Novartis Ag 295.74 Bn 259.73 Bn 11.24 Bn 32.97%
6 Astrazeneca 260.04 Bn 233.73 Bn 12.86 Bn 20.57%
7 Amgen 235.18 Bn 190.57 Bn 7.24 Bn 34.95%
8 Gilead Sciences 193.02 Bn 167.22 Bn 6.22 Bn -133.21%
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn 28.37%
10 Scinai Immunotherapeutics 163,440.56 -8.10 Mn -1.25 Mn -466.52%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -466.52%
Mar 31, 2026 -504.50%
Jun 30, 2025 -1,173.80%
Mar 31, 2025 -267.58%
Dec 31, 2024 -1,098.54%
Sep 30, 2024 -1,440.48%
API Access

Scinai Immunotherapeutics Operating Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=operating-margin&ticker=SCNI&period=max&api_key=YOUR_API_KEY